Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2024Journal of the Advanced Practitioner in Oncology

Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJustin ArnallLLLindsey LyleDMDonald C. Moore

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Arnall et al. (2024) studied this question.

synapsesocial.com/papers/68e6c930b6db6435876473e4https://doi.org/10.6004/jadpro.2024.15.8.6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advances in pharmacotherapy for myelofibrosis: what is the current state of play?2024
  2. 2JAK inhibitor selection in challenging scenarios of myelofibrosis: a review2025
  3. 3Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors2026
  4. 4Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence2026
  5. 5Comparative efficacy and safety of JAK inhibitor-based strategies in JAK inhibitor-naïve myelofibrosis: A systematic review and network meta-analysis2026